Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
Author:
- 1 October 2010
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 37 (5) , 430-439
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturationProceedings of the National Academy of Sciences, 2009
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 + CD4 + regulatory T cellsProceedings of the National Academy of Sciences, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infectionJournal of Experimental Medicine, 2006
- Tissue expression of PD-L1 mediates peripheral T cell toleranceJournal of Experimental Medicine, 2006